What we do Pfizer Ltd manufactures and markets pharmaceutical products across 15 therapeutic areas, serving nearly 185 countries with innovative medicines and vaccines. |
Founded in 1,950 |
Market share Among top 10 pharmaceutical companies in India by market share post-merger with Wyeth Ltd. |
Problem solved Provides specialized medicines addressing chronic diseases, vaccines, immunology, oncology, and hospital care, improving patient health outcomes. |
Top clients or who we serve Serves healthcare providers, hospitals, and patients across India and global markets, operating B2B, B2C, and institutional sales. |
Key management Ms. Meenakshi Nevatia (Managing Director), Mr. Amit Agarwal (Executive Director - Finance & CFO), Mr. P Rengan (Executive Director - Plant Operations). |
Our journey and innovations First Indian pharma company to start clinical research; launched multiple innovative drugs; merged with Wyeth India; advanced digital and manufacturing capabilities. |
Where we operate India (primary market) and exports to global markets including nearly 185 countries worldwide. |
Top products or what we offer 150 specialized medicines in Internal Medicine, Oncology, Hospital Care, Vaccines, Inflammation & Immunology, Rare Diseases across prescription and hospital segments. |
Top brands Corex, Becosules, Dolonex, Gelusil, Minipress XL, Benadryl, Eliquis, Enbrel, Prevenar 13, Neksium, Zavicefta, Betrecep. |
Raw materials needed Active pharmaceutical ingredients, bulk drugs, chemical intermediates sourced internationally and domestically. |
Raw materials supplier Pfizer Service Company BVBA, Belgium and other approved global suppliers. |
Recurring vs cyclical contribution Revenue primarily recurring through steady sales of pharmaceuticals and vaccines, with some cyclical impacts due to regulatory changes. |
Our industry position Market leader in pneumococcal vaccines and key therapies; strong presence in chronic and hospital care segments in India. |
Financial highlights FY 2025 revenue Rs.2,128 crore; profit before tax Rs.1,016 crore; net profit Rs.768 crore; consistent growth and strong margins. |
Geographical revenue split India accounts for 96%+ revenue; minor contributions from outside India exports. |
Order book Not explicitly disclosed; ongoing pharmaceutical supply agreements and hospital contracts. |
Whats driving growth New product launches, digital engagement, expanded HCP reach, hospital segment growth, and government health initiatives. |
Our future plans Expand advanced therapies, enhance vaccine portfolio, invest in manufacturing, digital innovation, and strengthen supply chain. |
Our green promise Solar energy use reducing carbon emissions by 53%; waste minimization and green manufacturing practices in place. |
Our people and values Diverse workforce emphasizing meritocracy, inclusive culture with focus on leadership development and employee well-being. |
Key challenges ahead Regulatory complexities, pricing pressures, competition from generics, and global economic uncertainties. |
Interesting facts First pharma company in India to start clinical research; Guinness World Record for largest healthcare oath-taking online campaign. |
Risks and strategy Mitigates regulatory and market risks via compliance, robust governance, portfolio optimization, and stakeholder engagement. |
